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Abstract 
Background: The chemokine interleukin-8 (CXCL8) is a key mediator of inflammation in 
airways of patients with cystic fibrosis (CF). Glycosaminoglycans (GAGs) possess the ability 
to influence the chemokine profile of the CF lung by binding CXCL8 and protecting it from 
proteolytic degradation. CXCL8 is maintained in an active state by this glycan interaction 
thus increasing infiltration of immune cells such as neutrophils into the lungs. As the 
CXCL8-based decoy PA401 displays no chemotactic activity, yet demonstrates glycan 
binding affinity, the aim of this study was to investigate the anti-inflammatory effect of 
PA401 on CXCL8 levels, and activity, in CF airway samples in vitro. 
Methods: Bronchoalveolar lavage fluid (BALF) was collected from patients with CF 
homozygous for the ΔF508 mutation (n=13). CXCL8 in CF BALF pre and post exposure to 
PA401 was quantified by ELISA. Western blot analysis was used to determine PA401 
degradation in CF BALF. The ex vivo chemotactic activity of purified neutrophils in response 
to CF airway secretions was evaluated post exposure to PA401 by use of a Boyden chamber-
based motility assay. 
 Results: Exposure of CF BALF to increasing concentrations of PA401 (50-1000 pg/ml) over 
a time course of 2-12 hours in vitro, significantly reduced the level of detectable CXCL8 
(P<0.05). Interestingly, PA401 engendered release of CXCL8 from GAGs exposing the 
chemokine susceptible to proteolysis. Subsequently, a loss of PA401 was observed (P<0.05) 
due to proteolytic degradation by elastase like proteases. A 25% decrease in neutrophil 
chemotactic efficiency towards CF BALF samples incubated with PA401 was also observed 
(P<0.05).  
Conclusion: PA401 can disrupt CXCL8:GAG complexes, rendering the chemokine 
susceptible to proteolytic degradation. Clinical application of a CXCL8 decoy, such as 
PA401, may serve to decrease the inflammatory burden in the CF lung in vivo. 
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1. Introduction 
Cystic fibrosis (CF) is the most common lethal genetic disease in Caucasians that is 
caused by mutations in the gene encoding the CF transmembrane conductance regulator 
(CFTR) chloride channel (Riordan et al., 1989). CF patients suffer from persistent pulmonary 
infections accompanied by chronic neutrophil-dominated inflammation that results in severe 
progressive lung injury. Mechanisms for how reduced CFTR function leads to chronic lung 
disease in CF include altered ion transport across the airway epithelium and dehydration of 
the airway surface layer (Matsui et al., 1998). The dehydrated airways are lined with thick 
mucus which contains elevated levels of anionic glycosaminoglycans (GAGs) produced on 
the bronchial epithelial cell surface (Reeves et al., 2011a). GAGs are unbranched, O-linked 
linear polysaccharide chains normally linked to a core protein (to form proteoglycans) located 
on the cell surface of almost all eukaryotic cell types (Adage et al., 2012; Rek et al., 2009). 
The immobilization of chemokines, specifically CXCL8 by GAGs plays a major role in the 
establishment of haptotactic gradients that contribute to the recruitment of leukocytes through 
the endothelium during inflammatory exacerbations (Proudfoot et al., 2003). GAGs in the 
lung are located on bronchial cells in the interstitial space between the capillary endothelium 
and the alveolar epithelium and the most abundant include heparan sulphate (HS) and 
chondroitin sulphate (CS) (Solic et al., 2005; Suki et al., 2005). In lung tissue CXCL8 has 
been demonstrated to bind specific regions depending on the presence of HS and CS and 
disruption of the GAG binding domain of CXCL8 or the removal of HS and CS leads to a 
significant reduction in the detection of this chemokine (Frevert et al., 2003). Moreover, 
increased concentrations of GAGs have been found in BALF from children with CF (Bhaskar 
et al., 1998; Hilliard et al., 2007) and secretion of HS (Solic et al., 2005), CS (Khatri et al., 
2003; Rahmoune et al., 1991) and  hyaluronic acid (Sahu, 1980; Wyatt et al., 2002) is 
markedly increased in bronchial cells and CF tissues. GAGs have also been shown to 
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influence the chemokine profile of the CF lung by binding and stabilizing CXCL8 in its 
active form thus promoting the activation and infiltration of neutrophils (Reeves et al., 2011b; 
Schlorke et al., 2012).  
PA401 is a recombinant therapeutic protein developed by ProtAffin Biotechnologie 
AG using its patented CellJammer® technology, an engineering platform used to introduce 
heightened GAG binding affinity into wild type GAG binding proteins and to disrupt  
receptor binding function (Adage T, 2012; Adage et al., 2012). CXCL8 was chosen as a 
target for this engineering strategy due to its association with HS and its involvement in 
numerous neutrophil driven inflammatory diseases including CF, chronic obstructive 
pulmonary disorder (COPD), rheumatoid arthritis, psoriasis and Crohn’s disease (Yang et al., 
1999). The recombinant CXCL8 decoy molecule is engineered with a deletion of the first six 
amino acids including the ELR motif which is essential for receptor binding of human 
CXCL8. Therefore, disruption of the protein sequence in this area inhibits the chemokine’s 
interaction with its specific G protein-coupled receptors CXCR1 and CXCR2 on leukocytes. 
In addition, non-crucial amino acids in the GAG binding site were replaced with basic amino 
acid residues to increase the GAG binding affinity of the chemokine (Adage et al., 2012). 
With these engineered mutations the novel CXCL8 decoy is capable of rapid binding to 
endothelial GAGs without binding to GPCRs, thus displacing wild type CXCL8 (Bedke et al., 
2010). The aim of the present study was to investigate the ability of PA401 to disrupt the 
interaction between native CXCL8 and protective GAGs in BALF samples of people with CF, 
thus rendering the chemokine susceptible to clearance. Some of the results of this study have 
been previously reported in abstract form (McElvaney OJ, 2013).  
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2. Materials and methods 
2.1. Chemicals and reagents 
All chemicals and reagents were purchased from Sigma Aldrich Chemical Co. Ltd., Dublin, 
Ireland unless indicated otherwise. PA401 (CXCL8 Δ6 F17K F21K E70K N71K) was 
generated by ProtAffin  Biotechnologie AG, Graz, Austria, according to published protocols 
(Falsone et al., 2013).  
 
2.2. Patient recruitment and sample collection  
Patients with CF homozygous for the ΔF508 mutation (n=13; age 23.6  4.13 mean ± SD; % 
forced expiratory volume in 1 second (FEV1) 56.3  21.65 predicted) were recruited to this 
study. BALF samples were collected from patients attending Beaumont Hospital and full 
informed consent was obtained pre-procedure according to a protocol approved by Beaumont 
Hospital Ethics Committee. BAL was performed by instilling and aspirating 1 ml/kg of sterile 
normal saline into the lingula and the right middle lobe. Obtained BALF was then centrifuged 
at 500 x g for 10 min at 4 °C and the cell free supernatant was aliquoted and stored at -80 °C.  
 
2.3. Native PAGE and Western blot analyses. 
BALF (20 µg protein) or 2 ng carrier free recombinant human CXCL8 (RhCXCL8; Biovision 
Inc. Milpitas, CA, USA) as a positive control were subjected to native gel electrophoresis in 
NativePAGE Novex 4-16 % (w/v) Bis-Tris gels (Innovagen, Lund, Sweden). Gels were run 
at 130 V for 1.5 h and were stained with Alcian Blue Solution (Merck Millipore) or Azure A 
chloride stain overnight (Powell et al., 2010) and then destained with ultra pure water.  
For Western blot analysis, proteins were transferred onto polyvinylidene difluoride 
(PVDF) membrane at 30 V for 1.5 h using a wet blotter. RhCXCL8 was loaded in order to 
visualize migration of the chemokine. Membranes were blocked for 1 h in 3 % (w/v) dry milk 
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and 1 % (w/v) bovine serum albumin (BSA) in phosphate buffered saline (PBS) containing 
0.05 % (v/v) Tween-20 and then incubated overnight in 1 µg/ml monoclonal mouse anti-
CXCL8 specific Ab (MAB208; R&D Systems, Abingdon, UK) or 0.3 μg/ml polyclonal 
rabbit hCAP-18 specific Ab (Innovagen, Lund, Sweden). The secondary Ab were HRP-
linked anti-mouse IgG or HRP-linked anti-rabbit IgG (Cell Signalling Technology, Danvers, 
MA, USA) incubated at room temperature for 1 h. Immuno-reactive protein bands were 
visualized employing Immobilon Western chemiluminescent horseradish peroxidase (HRP) 
substrate (Millipore, MA, USA) on the Syngene G:Box chemi XL gel documentation system 
(Synoptics, Cambridge, UK). Alternatively, immuno-reactive protein bands were visualized 
employing SuperSignal® West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, 
USA) after exposure to Kodak® X Omat LS Film. 
 
2.4. Surface Plasmon Resonance (SPR) Affinity Measurements  
Kd values for PA401 and CXCL8 binding to immobilized HS were determined by SPR 
measurements at 25 °C on a BiacoreX100 system (GE Healthcare, Uppsala, Sweden) as 
recently described (Gerlza et al., 2014). In short, PBS plus 0.005 % (w/v) Tween (Merck, 
Darmstadt, Germany) was used as a running buffer. Biotinylated GAGs were immobilised on 
C1 sensor chips (GE Healthcare) which were activated with EDC/NHS and coated with 
neutravidin (0.2 mg/mL in acetate buffer pH 4). For each binding experiment, 7 different 
concentrations of the respective PA401 or CXCL8 were measured in quadruplicates. Contact 
times for all injections and dissociations were 120 s at 30 μL/min. The regeneration solution 
(1 M NaCl) was enclosed directly after each dissociation time with 30 μL/min and 60 s 
contact time after each cycle. The maximum response signals of protein binding to the GAG 
surface, corresponding to the plateaus of the respective sensorgrams, were used for Scatchard 
plot analysis and the calculation of equilibrium Kd values. 
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 2.5. Enzyme linked immunosorbent assay (ELISA) measurements in pooled CF BALF. 
The concentration of CXCL8 or PA401 was measured by ELISA conducted in accordance 
with the manufacturer’s instructions (R&D Systems and ProtAffin, respectively). In brief, 96-
well plates (Nunc, Naperville, IL) were coated with 100 l mouse IgG1 anti-human 
CXCL8/IL-8 (Cat # MAB208, R&D Systems, diluted to 2 g/ml)) or monoclonal rat anti-
PA401 (# 8A12, ProtAffin, diluted to 7.5 g/ml) in Voller’s Solution (15 mM NaCO3, 35 
mM NaHCO3, 3 mM NaN3, pH 9.8)). The plate was covered and incubated at 4 °C overnight. 
The plate was washed with 200 μl of Washing Buffer (PBS containing 0.1 % (v/v) Tween 20) 
three times and blocked for 1 h by adding 200 μl of Blocking Buffer (PBS containing 1 % 
(w/v) BSA) to block non-specific binding sites in the coated wells. Standards and samples 
(100 l) were added to each well for 2 h at room temperature. In additional experiments to 
investigate the effect of GAGs on CXCL8 quantification, 100 pg of CXCL8 was pre-
incubated with HS and CS at a ratio of 1:10, respectively, for 20 min prior to addition to the 
ELISA plate for 2 h. In a subset of experiments protease inhibitors (1 mM 
phenylmethanesulfonyl fluoride (PMSF), 10 µg/ml Nα-tosyl-L-lysine chloromethyl ketone 
hydrochloride (TLCK) and Complete Mini tablet (Roche, Basel, Switzerland)) were added 
after this 2 h incubation. The plate was washed with Washing Buffer three times and then 
incubated with 100 μl HRP-conjugated antibody (human CXCL8/IL-8 biotinylated Affinity 
Purified PAb was used for both CXCL8 and PA401 ELISAs, R&D Systems, Cat # BAF208) 
diluted to 200 ng/ml in Blocking Buffer. The plate was incubated at room temperature for 1 h 
and then washed with Washing Buffer three times. For development, streptavidin-horseradish 
peroxidase (HRP) conjugate (R&D Systems), followed by 2,2'-azino-bis(3-
ethylbenzothiazoline-6-sulphonic acid)  (ABTS) was employed with absorbance of each well 
recorded at 405 nm. IL-6 in BALF was determined by sandwich ELISA (R&D Systems) 
according to the manufacturer’s instructions.   
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2.6. Treatment of BALF samples 
To assess the effect of PA401 on CXCL8 BALF levels, CF BALF was pooled (n=8) and 
diluted using notmal saline (0.9 % w/v NaCl) to achieve a final CXCL8 concentration of 
1000 pg/ml. Increasing concentrations of PA401 (0, 50, 100, 200, 400, 600, 800 or 1000 pg 
(ProtAffin  Biotechnologie AG)) were then added in 1 ml reactions. The in vitro effect of 
PA401 was also evaluated by incubating individual CF BALF samples with pre-determined 
CXCL8 levels with an equal concentration of PA401. Reactions were incubated for 0, 2, 4, 
12 and 24 h at 37 °C and at specific time points reactions were frozen. In a subset of 
experiments prior to freezing, protease inhibitors (1 mM PMSF, 10 µg/ml TLCK and 
Complete Mini tablet) were added to each sample to halt CXCL8 protein degradation. 
In additional experiment, BALF samples containing protease inhibitors (10 µg/ml 
TLCK, 10 µg/ml leupeptin, 10 µg/ml pepstatin A, 1 mM PMSF) were pooled (n=4) and 
diluted to contain 1000 pg/ml CXCL8 as measured by ELISA. Samples were either left 
untreated or treated with 600 pg/ml PA401, 600 pg/ml PA401 with 250 µg/ml HS or 150 
µg/ml heparitinase II and 100 µg/ml chondroitinase ABC for 2 h at room temperature. 
Samples were subjected to native gel electrophoresis and Western blot analysis.  
For experiments investigating displacement and degradation of CXCL8 by PA401 
pooled BALF samples (n=4) were diluted to contain 1000 pg/ml CXCL8 as measured by 
ELISA and were treated with 600 pg/ml PA401 for 1, 5, 15, 30, 60 or 120 min at room 
temperature with and without protease inhibitors. Samples were subjected to native gel 
electrophoresis to examine displacement of CXCL8 from GAGs or were subjected to SDS-
PAGE to determine degradation of CXCL8, followed by Western blot analysis. 
 
2.7. Proteolytic degradation of PA401 
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Pooled undiluted CF BALF (20 µl) was pre-incubated for 1 h on ice in the presence or 
absence of specific protease inhibitors (2 µl of: 500 mM ethylenediaminetetraacetic acid 
(EDTA), 200 mM pefabloc, 500 mM PMSF, 10 g/ml leupeptin, or 5 mg/ml E64). 
Subsequently these samples were incubated with PA401 (100 ng) at 37 °C for 2 h. After the 
reaction time SDS-PAGE loading buffer (5 µl) was added and samples were boiled at 95 °C 
for 5 min. Denatured samples were subjected to SDS-PAGE in pre-cast NuPAGE 4-12 % 
(w/v) gradient gels (Invitrogen) and Western blot analysis was performed employing 7.5 
µg/ml monoclonal rat anti-PA401 Ab (MAB8A12; ProtAffin). The secondary Ab was HRP-
linked anti-rat IgG (Cell Signalling Technology) To examine proteolysis of CXCL8 and 
PA401 by serine protease, 25 nM (4 ng/20 µl) of either CXCL8 or PA401 were incubated 
with varying concentrations of proteinase 3 (PR3) or cathepsin G (CathG) ranging from 100 
to 800 nM for 2 h at 37 °C. Proteolysis was stopped by adding denaturing SDS-PAGE sample 
buffer and samples were analysed by Western blot analysis.   
 
2.8. Preparation of human neutrophils and migration assays 
Blood was isolated from healthy control volunteers with no respiratory symptoms and who 
were not receiving medication. Blood was obtained in 7.5 ml heparinised S-monovette tubes 
(Sarstedt Ltd, Ireland) and neutrophils were purified by dextran sedimentation and 
Lymphoprep (Axis-Shield PoC AS, Norway) centrifugation (Reeves et al., 2013). Purified 
cells (2.5 x 10
5
/200 l) were resuspended in PBS (pH 7.4) containing 5 mM glucose (PBS-G). 
Purity of isolated neutrophils was validated by flow cytometric analysis using a monoclonal 
antibody against CD16b, a specific neutrophil marker (Bergin et al., 2014; Saeki et al., 2009). 
Neutrophil viability was assessed by Trypan Blue exclusion assay and the potential of PA401 
to induce neutrophil apoptosis was excluded by using an Annexin V-FITC Apoptosis Kit 
(BioVision Inc. Milpitas, CA, USA). Results confirmed viability of neutrophils above 98 % 
and the purity of isolated neutrophils was greater than 96 %.  
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Migration assays were performed by measuring the percentage of neutrophils 
migrating towards CF BALF (containing 1000 pg of CXCL8/ml) treated with 0, 200, 400 or 
600 pg/ml PA401 for 4 h, by employing a multiwell chemotaxis chamber (Neuro Probe, Inc., 
USA) and polyvinylprrolidone-free polycarbonate filters (10 m thick with 5 m pores). The 
stimulant (CF BALF ± PA401) was placed in the lower chamber (total volume of 90 l) and 
purified neutrophils in the upper chamber (2.5 x 10
5
cells/200 l). Neutrophil chemotaxis was 
quantified over 30 min at 37 ºC in a humidified atmosphere (5 % CO2). The chemotaxis 
chamber was then disassembled and the polycarbonate filter fixed with methanol and cells 
stained using Speedy Diff solutions (Clin-tech Ltd, Guildford, UK). The
 
number of migrating 
neutrophils was determined microscopically employing a Nikon Eclipse TS100 microscope
 
with 10 standardized x 400-high power
 
fields counted for each well. For comparative analysis 
the number of neutrophils migrating in PBS was set at a migration index of 1.  
 
3. Statistical analysis. 
Each individual experiment was performed at least in triplicate and repeated on three or more 
independent occasions. Results are presented as mean ± standard error of the mean (SEM).  
GraphPad Prism software version 4.03 for Windows was used for statistical analysis of the 
data (GraphPad Software, San Diego, CA, USA). One Way-ANOVA was performed when 
comparing three or more groups. Unpaired Student’s t-test analysis was used for comparison 
between two data sets. Statistically significant differences were determined when a P-value 
was < 0.05, denoted as * or ** for P<0.01. 
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4. Results 
4.1. PA401 reduces CXCL8 levels in CF BALF  
Increased expression of GAGs, in particular heparan sulphate (HS), has been reported in 
individuals with CF (Kuschert et al., 1999). This altered expression profile has been linked to 
the sustained inflammatory response in the CF airways. As chemokine-GAG complexes are 
stable in gel shift/mobility experiments (Witt and Lander, 1994), in initial experiments we 
investigated the CXCL8 protein profiles in BALF of individuals with CF using native-PAGE 
and Western blot analysis. Carrier free RhCXCL8 (8 kDa) illustrated a fast rate of migration 
by native gel electrophoresis (Fig. 1A), but in contrast CXCL8 present in CF BALF (n=13) 
ran as a high molecular weight smear, most likely representing a GAG complexed form of the 
chemokine as previously described (Reeves et al., 2011b). Alcian blue, the most widely used 
cationic dye for demonstration of GAGs, and Azure A for sulphated material (Powell et al., 
2010), confirmed the presence of GAGs in all CF BALF samples tested (Fig. 1B).                                                                                     
We next compared the HS binding affinity of PA401 to CXCL8. The results show 
clearly that PA401 binds with a significantly (30-fold) higher affinity to HS compared to the 
wild type chemokine (Fig. 2A). Regarding the binding kinetics of this interaction, we 
observed that the higher binding affinity of PA401 is the result of a much slower off rate 
rather than of a faster on rate, the latter of which was very similar between the two proteins 
(data not shown).  
Ensuing experiments investigated the effect of a single concentration of PA401 on the 
level of CXCL8 in CF-BALF. Pooled CF-BALF diluted to contain a fixed amount of 
endogenous CXCL8 (1000 pg/ml) was incubated with PA401 (600 pg/ml) at 37 
o
C for 2 h 
and the level of CXCL8 determined by native gel electrophoresis and immune-blotting. As 
demonstrated in Fig. 2B, reduced CXCL8 immunoband intensity was observed in CF BALF 
treated with PA401, an effect reversed by pre-exposing PA401 to 100 fold excess HS, thus 
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verifying the interaction of PA401 with GAG matrices in CF samples. Moreover, as GAGs 
including HS interact with chemokines such as CXCL8, we evaluated the effect of digesting 
GAGs on CXCL8 expression. Post treatment of CF-BALF with chondroitinase ABC and 
heparitinase II, samples were subjected to native gel electrophoresis and Western blot 
analysis. As illustrated in Fig. 2B, an immunoreactive band corresponding to complexed 
CXCL8 was absent in samples treated with GAG lyases. Moreover, samples treated with 
GAG lyases in the presence of protease inhibitors (0.2 M pefabloc SC and Complete Mini 
tablet) showed greater levels of immuno-reactivity for the free form of CXCL8 (Fig. 2C). To 
further explore the effect of PA401 on CXCL8 levels in CF BALF a time course was 
performed by incubating CF BALF, with a predetermined concentration of endogenous 
CXCL8 (1000 pg/ml), with PA401 (600 pg/ml) for 1, 5, 15, 30, 60 or 120 min at 37 
o
C. By 
use of a monoclonal antibody for the detection of CXCL8, results of Western blot analysis 
demonstrated that BALF levels of CXCL8 decreased over time as visualized on both native 
(Fig. 2D; top panel) and denaturing gels (Fig. 2D; bottom panel). Collectively, these results 
demonstrate the interaction of CXCL8 with GAGs in CF airway samples, and the reduction 
in the level of CXCL8 detected post exposure to PA401 forms the foundation of this study.  
As immunoblots offer only semiquantitative data, we next investigated the effect of 
PA401 on the levels of CXCL8 in CF-BALF by ELISA. Pooled CF-BALF diluted to contain 
a fixed amount of native CXCL8 (1000 pg/ml) was incubated with increasing concentrations 
of PA401 ranging from 50 pg/ml to 1000 pg/ml at 37 
o
C for 0, 2, 4 or 12 h and the level of 
CXCL8 in each reaction determined by ELISA. Results illustrated that CF BALF treated with 
PA401 had significantly less CXCL8 than untreated samples (P<0.01 at the 2 h time point, 
n=3), with negligible levels of CXCL8 detected after 12 h incubation in all samples (Fig. 3). 
A concern in relation to this experiment was the natural degradation of CXCL8 observed in 
untreated samples thereby skewing data towards possibly overestimating the effect of PA401. 
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At the 0 h time point the concentration of CXCL8 detected in samples containing 1000 pg/ml 
PA401 had decreased to 12 % of the untreated sample and it was postulated that this effect 
may in part be due to continued degradation of CXCL8 during the 2 h antigen-capture phase 
of the ELISA.  
To challenge this hypothesis, CF BALF containing 1000 pg/ml CXCL8 was incubated 
with an equal concentration of PA401 and after 2 h incubation protease inhibitors were added 
prior to ELISA for CXCL8 quantification (Fig. 4A). In agreement with previous data, 
addition of PA401 (1000 pg/ml) significantly reduced the level of CXCL8 to 7.2 % of the 
untreated control sample (n=3; P<0.01). In comparison however, inclusion of protease 
inhibitors (0.2 M pefabloc and complete mini tablets) lessened the observed effect of PA401, 
although this was still significantly reduced compared to untreated control samples (52 % 
reduction; P<0.01). Ensuing experimental results demonstrated that addition of protease 
inhibitors immediately after the incubation period at 37 
o
C prevented the additional 
proteolysis of CXCL8 during the ELISA incubation (Fig. 4B). A dose dependent decrease in 
BALF CXCL8 levels was evident following a 2 h incubation with PA401, that reached a 
plateau at 600 pg/ml (Fig. 4B). The concentration of CXCL8 at the 2 h time point was 
significantly decreased by 42 % following exposure to 600 pg/ml PA401 compared to the 
cytokine level detected in untreated BALF (P<0.05). Of importance, a comparison of the 
quantification of CXCL8 (100 pg) pre-exposed to a mixture of both HS and CS was 
performed (Fig. 4C). ELISA results revealed that detection of CXCL8 was significantly 
decreased when incubated with GAGs at a ratio of 1:10 (P<0.05). These results are in line 
with previously published data (Reeves et al., 2011b) and demonstrate that levels of CXCL8 
in CF BALF samples, and the effectiveness of PA401, may be underestimated. 
 In the described experiments we have confirmed the effect of PA401 in pooled CF 
BALF and therefore in subsequent tests individual, undiluted, BALF samples were employed 
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(Fig. 5). PA401 was added to CF BALF at the equivalent predetermined CXCL8 
concentration. Results indicate that PA401 significantly reduced CXCL8 levels in all CF 
BALF samples tested but the effect varied between individual patients (n=4). At 4 h post 
PA401 treatment the concentration of CXCL8 in CF#1 BALF decreased by 35 % (P=0.01), 
CF#2 BALF decreased by 29 % (P=0.05), CF#4 decreased by 15 % (P=0.05) and CF#5 
BALF levels of CXCL8 decreased by 33 % (P=0.01) (Fig. 5). In control experiments the 
PA401 decoy used in assays (0-1000 pg/ml) was not detected by the CXCL8 ELISA 
confirming no cross reactivity between the decoy and native CXCL8 in pooled CF BALF. 
PA401 was found to have no effect on BALF levels of other inflammatory mediators 
including IL-6 or the anti-microbial peptide hCAP-18 (result not shown).  
 
4.2. PA401 is proteolytically degraded in CF BALF. 
Quantification of PA401 by ELISA employing a monoclonal rat anti-PA401 (# 8A12, 
ProtAffin) revealed that the concentration of decoy present in CF BALF decreased as the 
time of incubation increased (Fig. 6A). Specifically, at the 2 h time point the level of PA401 
present in samples initially containing 1000 pg/ml had decreased by 53 % (P<0.05). These 
results indicate that the decoy can quickly lead to the degradation of native CXCL8 in CF 
BALF, and in turn, is subsequently degraded and thus build-up of the recombinant protein is 
unlikely. Western blot analysis was used to elucidate the protease(s) responsible for 
degradation of PA401 in CF BALF. PA401 (100 ng) was incubated for 2 h at 37 °C in pooled 
undiluted CF BALF followed by separation by SDS-PAGE and Western blot analysis 
employing monoclonal rat anti-PA401 Ab. An immuno-reactive band for PA401 was clearly 
visible at approximately 8 kDa. In contrast however, degradation of the decoy was evident 
after 2 h incubation in CF BALF (Fig. 6B). To identify protease(s) responsible for cleavage 
and destruction of PA401 in CF BALF, various protease inhibitors were pre-incubated with 
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CF BALF before adding PA401. The use of broad range protease inhibitors targeting 
elastase-like, trypsin-like and cysteine-like proteases and metalloproteases identified elastase-
like proteases as playing a key role in the proteolytic cleavage of PA401. As shown in Fig. 
6B, PMSF and pefabloc inhibited the cleavage of PA401, whereas leupeptin and E64 
(trypsin- and cysteine-like), and EDTA (metalloproteinase-like) had no or little effect. Taken 
together, these results show that elastase-like proteases may be involved in the degradation of 
PA401 within the CF lung. It has previously been shown that neutrophil elastase is capable of 
degrading CXCL8 (Leavell et al., 1997) and for this reason we examined the ability of other 
neutrophil derived serine proteases to cleave CXCL8 and PA401. A dose response 
experiment was performed by incubating RhCXCL8 or PA401 (25nM) with PR3 or CathG 
(100, 200, 400 or 800 nM) for 2 h at 37 
o
C. Fig. 6C shows that levels of RhCXCL8 and 
PA401 detected by Western blot analysis decreased with increasing enzyme concentrations 
and 400 nM fully degraded the chemokine and decoy after 2 h incubation. No fragmentation 
products were detected for either PA401 or RhCXCL8 by immunoblotting. These results 
confirm that CXCL8 and PA401 are equally susceptible to proteases present within the CF 
airways.  
  
4.3. CF BALF induced neutrophil chemotaxis is reduced in cells exposed to PA401 treated 
BALF.  
Neutrophilic inflammation is partially explained by the stability of CXCL8 within the CF 
lung and binding to HS enhances neutrophil responses to CXCL8 (Webb et al., 1993). For 
this reason we investigated the impact of PA401 induced clearance of CXCL8 on associated 
neutrophil migration in vitro. Firstly, the robustness of this assay was demonstrated by 
measuring the dose-dependent migration of neutrophils towards CXCL8 (1 or 10 ng) (Fig. 
7A). Subsequently, pooled CF BALF (n=4) containing 1000 pg/ml CXCL8 was exposed to 
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PA401 (0, 200, 400 or 600 pg/ml) for 4 h. The migration index of healthy control neutrophils 
in response to CF-BALF was compared pre- and post-PA401 treatment with results 
illustrating a significant 16% (P<0.05) decrease in migration activity in samples exposed to 
400 pg/ml of PA401 compared to untreated BALF. At a higher concentration, PA401 (600 
pg/ml) reduced the neutrophil migration index produced by CF BALF by 25 % (P<0.05) (Fig. 
7B). 
Taken together, these in vitro results indicate that GAG-immobilised CXCL8 
maintains activity and in vitro, post-PA401 treatment, CXCL8 is solubilised from GAGs 
rendering it susceptible to proteolysis. PA401 itself is also susceptible to degradation which is 
of little consequence as the beneficial effects of decreased levels CXCL8 are already evident 
by the weakened chemotactic capacity of CF-BALF.  
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5. Discussion 
The aim of this study was to evaluate the effect of a novel CXCL8 decoy molecule on native 
CXCL8 levels in CF BALF. Inflammation in the CF lung is mediated in part by the presence 
of increased concentrations of GAGs which stabilise active CXCL8 and protect it from 
proteolytic degradation, therefore establishing a chemotactic gradient and promoting the 
influx of destructive neutrophils (Kuschert et al., 1999). The GAG most successful at binding 
CXCL8 is heparan sulphate when in association with the core protein syndecan-1 (Marshall 
et al., 2003). Potential therapeutics that directly target inflammatory processes and remove 
the need for prolonged use of corticosteroids are highly desirable (Konstan and Davis, 2002). 
Inflammation that accompanies mucus accumulation in patients with CF is currently treated 
using a variety of aerosolized therapies (Konstan and Davis, 2002). Nebulized HTS 
contributes to rehydration of the airways and increases mucociliary clearance, and 
additionally reduces chemokine levels in CF BALF via the disruption of ionic interactions 
with GAGs (Reeves et al., 2012; Reeves et al., 2011b). Results of the present study indicate 
that clinical application of a CXCL8 decoy may serve to decrease the inflammatory burden in 
the CF lung in vivo. 
The effects of PA401 have been previously analysed using an in vitro flow system of 
leukocyte recruitment to primary human microvascular endothelium (Bedke et al., 2010). 
Application of the CXCL8 decoy molecule was found to inhibit neutrophil rolling and 
adherence. A similar experimental set up was used to analyse the effect of PA401 on 
monocyte adhesion employing the HDMED cell line. Under these experimental conditions 
the decoy caused decreased interaction between endothelial cells and monocytes and shear 
resistant adhesion of mononuclear cells to the endothelium was reduced (Bedke et al., 2010). 
The compound was also assessed in an in vivo model for kidney ischemia/reperfusion (I/R) 
and acute renal allograft damage in rats. Infiltration of neutrophils to the site of I/R has been 
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implicated in the acute rejection of transplanted allograft organs (Hirayama et al., 2006) and 
treatment with PA401 reduced acute damage to allograft kidneys (Bedke et al., 2010). The 
positive outcomes of these investigations lead to PA401 being granted orphan medicinal 
product status for use in delayed graft function after solid organ transplant by the EMA and 
FDA. The properties of PA401 have also been investigated in the context of inflammatory 
lung disease using a mouse model (Adage T, 2012). The subcutaneous administration of 
PA401 reduced the level of neutrophil infiltration detected in the BALF of chronic smoke 
induced and acute LPS induced models of murine lung inflammation (Adage et al., 2012). A 
murine model of mBSA (methylated BSA) - induced arthritis has been utilised to evaluate the 
systemic anti-inflammatory potential of PA401. The decoy was administered subcutaneously 
resulting in a decrease in neutrophil infiltration to the knee cavity as measured in knee lavage 
fluid (Falsone et al., 2013). The results obtained from animal studies thus far have been 
achieved by delivering the decoy intravenously. However, as the proposed mode of delivery 
for treatment of lung inflammation is via inhalation we sought to discover the effects of the 
decoy when directly applied to BALF of patients with CF. Within this study we have shown 
that exposure of pooled CF BALF to PA401 lead to a reduction in the concentration of native 
CXCL8 detected in CF BALF samples. The proposed mode of action for PA401 within the 
airways is the ability of the decoy to disrupt CXCL8:GAG interactions thus rendering native 
CXCL8 susceptible to proteolytic degradation by elastase like proteases. We have previously 
shown that upon release of CXCL8 from GAG matrices by HTS the chemokine is rendered 
unprotected and exposed to proteolysis by neutrophil elastase (Reeves et al., 2011b). This 
observation is also supported by work by Leavell et al., (1997) who demonstrated that 
incubation of CXCL8 with neutrophil elastase resulted in the loss of CXCL8 chemotactic 
activity in a dose- and time-dependent fashion, an effect incurred by proteolysis of CXCL8 
into undetectable small fragments (Leavell et al., 1997).  
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Despite the potential advantages of delivery of PA401 to the lungs, in vivo models 
would be necessary to evaluate presence of the decoy on the respiratory epithelial surface and 
penetration into the interstitium following aerosolization. One of the potential challenges with 
administration of PA401 is that the decoy itself is susceptible to degradation by proteases 
present in the airways. This occurrence may be prevented by rational design to improve the 
PA401 molecule rendering it less susceptible to proteolysis, but only if bioactivity is not 
influenced by this additional engineering. Indeed, the susceptibility of the drug to degradation 
closely mirrors challenges associated with aerosolization of recombinant secretory leukocyte 
protease inhibitor (SLPI) to the lungs of individuals with CF. SLPI is a potent inhibitor of 
neutrophil elastase, however, it has been shown that this antiprotease is vulnerable to 
degradation and inactivation by cysteinyl cathepsins (Taggart et al., 2001) and serine 
proteases, (Weldon et al., 2009) and thus the utilization of SLPI as effective therapy for 
airways disease presents some challenges. A solution to this conundrum was delivery of 
recombinant SLPI via a liposomal carrier which successfully protected the activity of SLPI 
against cathepsin L mediated proteolysis, whilst having no detrimental effect on SLPI access 
to intracellular sites of action in vitro (Gibbons et al., 2009). Such an approach may also 
prove useful in aerosolization of PA401 to prolong its activity and further studies would be 
required for confirmation. 
The results of this study demonstrate that as a consequence of PA401 exposure and 
reduced levels of CXCL8, there is a decrease in neutrophil chemotaxis in response to CF 
BALF. CXCL8 is a major chemotactic factor in CF and lowering the levels of CXCL8 in the 
CF airways could be expected to somewhat decrease neutrophil chemotaxis. It is however 
only one of a number of chemoattractants found in the CF airways. Leukotriene B4, formyl 
peptides, C5a, platelet activating factor (Mackerness et al., 2008) and more recently proline-
glycine-proline (Gaggar et al., 2008) are among other chemoattractants that contribute to 
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neutrophil influx. Nevertheless, in the present study we have demonstrated that disruption of 
GAG:CXCL8 interactions in CF BALF samples by PA401 was sufficient to significantly 
decrease the number of migrating neutrophils in vitro, with the potential for an effective anti-
inflammatory outcome in vivo.  
 
6. Conclusion 
In summary, treatment to specifically target chronic inflammation exacerbations in CF has 
largely been achieved with the use of inhaled medications such as antibiotics, corticosteroids 
and mucolytics (Flume et al., 2009). The CXCL8 decoy PA401 disrupts the interaction 
between GAGs and CXCL8, rendering CXCL8 susceptible to proteolytic degradation with 
subsequent decrease in neutrophil chemotaxis. Consequently, this decoy approach represents 
a novel way to treat the high levels of GAG bound CXCL8 present in the CF lung, which is a 
major contributing factor to lung morbidity in patients. 
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Figure Legends 
Fig. 1.  GAG expression profile and pattern of CXCL8 in BALF of individuals with CF.  
Native gel electrophoresis and Western blot analysis for CXCL8 in CF BALF (n=7). Carrier 
free recombinant human CXCL8 (Rh-CXCL8) was employed as a control to visualize protein 
migration. Western blot analysis confirmed that CXCL8 exists in a high molecular weight 
complex in CF BALF when compared to Rh-CXCL8. B; Native gels of CF BALF stained 
with Alcian Blue (top panel) or Azure A chloride stain (bottom panel). The Western blot and 
stained gels illustrated are representative results of one out of three separate experiments.  
 
Fig. 2. Levels of CXCL8 decrease in CF BALF following exposure to PA401.  
A; Kd values for PA401 and CXCL8 binding to immobilized HS determined by SPR. PA401 
binds with a significantly (30-fold) higher affinity to HS compared to the wild type 
chemokine. B; Pooled BALF samples containing 1000 pg/ml endogenous CXCL8 was either 
left untreated or was treated with PA401 (600 pg/ml), PA401 preexposed to HS (250 µg/ml) 
or GAG lyases (heparanase (150 µg/ml) and chondroitinase (100 µg/ml)) for 2 h.  Samples 
were subjected to native gel electrophoresis and Western blot analysis for CXCL8. C; CF 
BALF with and without GAG lyases and with protease inhibitors (0.2 M pefabloc SC and 
Complete Mini tablet) was subjected to native gel electrophoresis and Western blot analysis 
for CXCL8. The position of free and complexed forms of CXCL8 is indicated. D; Pooled CF 
BALF (n=4) was exposed to PA401 for 1, 5, 15, 30, 60 or 120 min and subjected to native 
(top panel) or denaturing (bottom panel) gel electrophoresis and Western blot analysis for 
CXCL8. The Western blots illustrated are representative results of one out of three separate 
experiments.  
 
30 
 
Fig. 3. Decreased CF BALF levels of CXCL8 post exposure to PA401 confirmed by 
ELISA. 
Pooled CF BALF (n=4) was exposed to increasing concentrations of PA401 for 0, 2, 4 or 12 
h and levels of CXCL8 were determined by ELISA. Statistical analysis across individual time 
points performed by One Way-ANOVA (*=P<0.05; **=P<0.01).   
 
Fig. 4: Detection of reduced levels of CXCL8 in CF BALF supplemented with proteases 
inhibitors post PA401 exposure.  
A; CF BALF (containing 1000 pg of CXCL8/ml) was either untreated or treated with 
protease inhibitors (PI;  0.2 M pefabloc and Complete Mini tablets) and subsequently either 
untreated or treated with PA401 (1000 pg) for 4 h. CXCL8 levels were detected by ELISA 
and expressed as pg/ml.  (**P<0.01 by Student’s t-test; NS = no significant difference. n=4 
independent experiments). B; Pooled CF BALF (n=4) was exposed to PA401 for 0, 1, 2 or 4 
h at increasing concentrations (0-600 pg/ml). After the indicated time points PI were added to 
prevent further CXCL8 degradation and levels were detected by ELISA (*P<0.05, **P<0.01 
by ANOVA; n=4 independent experiments).  C; ELISA analysis for CXCL8 (100pg) in the 
absence or presence of GAGs (1:10 ratio). Bars indicate standard error of the mean 
(**P<0.01 by Student’s t-test; n=3 independent experiments). 
 
Fig. 5. PA401 decreased CXCL8 levels in individual CF BALF samples.  
PA401 was added at a concentration equivalent to the predetermined level of CXCL8 in each 
undiluted CF BALF sample (n=4). Reactions were incubated at 37 
o
C for 4 h followed by the 
addition of PI and CXCL8 quantification by ELISA (Student’s t-test, **P<0.01, *P<0.05 
between treated and untreated respective samples; NS = non-significant). Bars indicate the 
mean ± SEM of n=3 independent experiments.    
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 Fig. 6. PA401 is proteolytically degraded in CF BALF. 
A; PA401 levels in pooled CF BALF (n=4) decreased over time as detected by ELISA  
employing a rat anti-PA401 Ab  (*P<0.05, **P<0.01 by Student’s t-test between the 1000 
pg/ml at time 0 h and 2 h or 4 h respectively; n=3 independent experiments). B: Immuno-blot 
showing PA401 (100 ng/ 20 μl) degradation in pooled CF BALF (n=6). PA401 was 
incubated in PBS as a negative control or CF BALF as a positive control (Con). CF BALF 
samples (20 μl) were pre-incubated with 2 μl of protease inhibitors; EDTA (500 mM), PMSF 
(500 mM),  pefabloc (Pef, 200 mM), Leupeptin (Leu, 10 mg/ml) or E64 (5 mg/ml). 
Subsequently, samples were incubated with PA401 (100 ng) at 37 °C for 4 h. PA401 
breakdown was primarily prevented by inclusion of elastase like inhibitors. C; Western blot 
analysis of the proteolytic degradation of RhCXCL8 and PA401 (25nM) by PR3 and CathG 
(100-800nM) for 2 h at 37 
o
C. Results presented in B and C are representative blots of 3 
separate experiments. 
 
Fig. 7. PA401 reduced CF BALF induced neutrophil migration. 
A; Mean migration index of purified neutrophils in response to CXCL8 (0, 1 or 10 ng). B; 
Induced mean migration index of purified neutrophils (2x10
5
 /200 µl) in response to CF 
BALF (containing 1000 pg of CXCL8/ml) was reduced post treatment with PA401 (200, 400 
or 600 pg/ml) for 4 h when compared to the untreated control. For comparative analysis cells 
in PBS were set as a migration index of 1. Three experiments each with five replicates were 
performed on separate days. Bars indicate standard error of the mean (*P<0.05 by Student’s 
t-test). 
 
 
 
32 
 
33 
 
34 
 
35 
 
36 
 
37 
 
38 
 
 
 
